Eure KARE invests in Europe, the UK, and Israel to unlock the potential of synthetic biology and microbiome research. The firm believes these fields can address critical global challenges—from healthcare innovations like cell therapies and gene therapies to environmental solutions such as biofuels and pollution control—by commercializing Europe’s strong scientific research base and creating new industries.
Bevorzugte Reifephase für die erste Finanzierung.
Cutting-edge synthetic biology and microbiome technologies with applications in healthcare, agriculture, energy, and environmental sustainability.
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Standard-Finanzierungsbetrag pro Runde.
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...
